Highly effective carbon supported-Pt75Au25 catalysts for oxygen reduction reaction (ORR) are prepared though titanium dioxide modification and post heat treatment. After accelerated durability test (ADT) of 1700 cycles, the ORR activity of PtAu/C catalysts modified by TiO2 and air heat treatment is 3 times higher than that of the commercial Pt/C. The enhancement of ORR activity is attributed to surface and structural alteration by air-induced Pt surface segregation and lower unfilled d states. On the contrary, for TiO2 modified and H2 treated PtAu/C catalysts, the deterioration of the ORR activity may be due to the loss of electrochemical surface area after ADT and the increase of d-band vacancy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/am404334k | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of age and performance status with adverse events in older adults with diffuse large B-cell lymphoma receiving frontline R-CHOP therapy: Alliance 151930, a secondary analysis of the phase III trial CALGB 50303.
J Geriatr Oncol
January 2025
Department of Oncology, Mayo Clinic, Rochester, MN, United States of America.
Introduction: Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) therapy is the standard of care for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). However, detailed delineation of toxicity data is limited and has not been examined by age. We sought to examine adverse event data in patients receiving R-CHOP from the Cancer and Leukemia Group B (CALGB) 50303 trial to determine if there were differences in grade 3+ toxicities by age cohort or ECOG performance status (PS), and if outcome was impacted by age cohort or toxicity occurrence.
View Article and Find Full Text PDFFDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma.
Clin Cancer Res
January 2025
United States Food and Drug Administration, Silver Spring, Maryland, United States.
On April 23, 2024, FDA granted accelerated approval to tovorafenib, a type II RAF kinase inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Efficacy was evaluated in FIREFLY-1 (NCT04775485), a single-arm, open-label, multicenter trial that enrolled patients 6 months to 25 years of age with relapsed or refractory pLGG with an activating BRAF alteration who had received prior systemic therapy. The major efficacy outcome measure was radiologic overall response rate (ORR), defined as the proportion of patients with complete response, partial response, or minor response as determined by blinded independent central review using Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria.
View Article and Find Full Text PDFDecoding Dual-Functionality in N-doped Defective Carbon: Unveiling Active Sites for Bifunctional Oxygen Electrocatalysis.
Small
January 2025
Institute of Nano Science and Technology, Sector-81, Knowledge city, S.A.S. Nagar, Punjab, 140306, India.
Oxygen electrocatalysis plays a pivotal role in energy conversion and storage technologies. The precise identification of active sites for oxygen reduction reaction (ORR) and oxygen evolution reaction (OER) is crucial for developing an efficient bifunctional electrocatalyst. However, this remains a challenging endeavor.
View Article and Find Full Text PDFFruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial.
Target Oncol
January 2025
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Background: Antiangiogenic inhibitors plus immune checkpoint inhibitors have synergistic antitumor activity and have improved treatment outcomes in patients with renal cell carcinoma (RCC).
Objective: We report the RCC cohort from a phase Ib/II study in Chinese patients evaluating the efficacy and safety of fruquintinib plus sintilimab in treating advanced clear cell RCC (ccRCC).
Patients And Methods: Eligible patients had pathologically confirmed advanced ccRCC.
Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib.
Ann Oncol
January 2025
David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address:
Background: Osimertinib is the standard first-line treatment for advanced epidermal growth factor receptor (EGFR)-mutated NSCLC. However, treatment resistance is inevitable and increased c-Met protein expression correlates with resistance. Telisotuzumab vedotin (Teliso-V) is an antibody-drug conjugate that targets c-Met protein overexpression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!